Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Indolinyl-Thiazole Based Inhibitors of Scavenger Receptor-BI (SR-BI)-Mediated Lipid Transport. ACS Med Chem Lett 2015 Apr 09;6(4):375-380

Date

10/20/2015

Pubmed ID

26478787

Pubmed Central ID

PMC4599563

DOI

10.1021/ml500154q

Scopus ID

2-s2.0-84927666208 (requires institutional sign-in at Scopus site)   11 Citations

Abstract

A potent class of indolinyl-thiazole based inhibitors of cellular lipid uptake mediated by scavenger receptor, class B, type I (SR-BI) was identified via a high-throughput screen of the National Institutes of Health Molecular Libraries Small Molecule Repository (NIH MLSMR) in an assay measuring the uptake of the fluorescent lipid DiI from HDL particles. This class of compounds is represented by ML278 (17-11), a potent (average IC50 = 6 nM) and reversible inhibitor of lipid uptake via SR-BI. ML278 is a plasma-stable, noncytotoxic probe that exhibits moderate metabolic stability, thus displaying improved properties for in vitro and in vivo studies. Strikingly, ML278 and previously described inhibitors of lipid transport share the property of increasing the binding of HDL to SR-BI, rather than blocking it, suggesting there may be similarities in their mechanisms of action.

Author List

Dockendorff C, Faloon PW, Yu M, Youngsaye W, Penman M, Nieland TJ, Nag PP, Lewis TA, Pu J, Bennion M, Negri J, Paterson C, Lam G, Dandapani S, Perez JR, Munoz B, Palmer MA, Schreiber SL, Krieger M

Author

Christopher Dockendorff PhD Assistant Professor, Organic and Medicinal Chemistry in the Chemistry department at Marquette University